Surmodics Inc (SRDX) 24.79 $SRDX
SurModics Up 17.0% Since SmarTrend Uptrend Call (SRDX)
Comtex SmarTrend(R) - Fri Jul 08, 1:30AM CDT
SmarTrend identified an Uptrend for SurModics (NASDAQ:SRDX) on January 28th, 2016 at $20.44. In approximately 5 months, SurModics has returned 16.96% as of today's recent price of $23.90.
SRDX: 24.79 (+0.13)
Zacks.com featured highlights: Copart, Tallgrass Energy GP, Vishay Intertechnology, W.R. Grace and SurModics
Zacks Equity Research - Zacks Investment Research - Thu Jun 30, 8:30AM CDT
Zacks.com featured highlights: Copart, Tallgrass Energy GP, Vishay Intertechnology, W.R. Grace and SurModics
SRDX: 24.79 (+0.13), GRA: 73.95 (-0.27), VSH: 12.13 (+0.05), CPRT: 50.01 (+0.16), TEGP: 24.24 (+0.37)
Invest in These 5 Efficient Stocks for Healthy Returns
Zacks Equity Research - Zacks Investment Research - Wed Jun 29, 7:03AM CDT
An investment strategy based on the efficiency level of a company is likely to lead to healthy returns across all market conditions.
SRDX: 24.79 (+0.13), GRA: 73.95 (-0.27), VSH: 12.13 (+0.05), CPRT: 50.01 (+0.16), TEGP: 24.24 (+0.37)
Myriad Genetics Buys Sividon Diagnostics, Gains EndoPredict
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 7:59AM CDT
With the global cancer diagnostic market currently expected to grow at a CAGR of 7.6% to $168.6 billion by 2020; we expect the Sividon acquisition to open up more opportunities for Myriad (MYGN) in this market.
BSX: 23.77 (-0.13), SRDX: 24.79 (+0.13), MYGN: 32.06 (+0.37), BAX: 46.49 (-0.16)
SurModics to Present at Jefferies Healthcare Conference
BusinessWire - Wed Jun 01, 7:05AM CDT
SurModics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced that Gary Maharaj, president and chief executive officer, and Andy LaFrence, vice president of finance and chief financial officer, will make a presentation to the investment community at the Jefferies Healthcare Conference in New York City on Tuesday, June 7, 2016, at 4 p.m. ET (3 p.m. CT).
SRDX: 24.79 (+0.13)
GNC Holdings Q1 Results Weak, Overseas Prospects Bright
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 7:01AM CDT
GNC Holdings (GNC) made a disappointing start to its first quarter of 2016 with the results squarely missing the Zacks Consensus Estimate.
BSX: 23.77 (-0.13), SRDX: 24.79 (+0.13), BAX: 46.49 (-0.16), GNC: 25.75 (+0.22)
Thermo Fisher to Buy FEI, Boost Electron Microscopy Platform
Zacks Equity Research - Zacks Investment Research - Tue May 31, 7:58AM CDT
The FEI deal is expected to be accretive to Thermo Fisher's (TMO) adjusted EPS by 30 cents in the first full year after close.
BSX: 23.77 (-0.13), SRDX: 24.79 (+0.13), TMO: 152.34 (-0.35), BAX: 46.49 (-0.16), FEIC: 106.79 (+0.01)
IDEXX Laboratories: Strong Instrument Placement Drives Q1
Zacks Equity Research - Zacks Investment Research - Mon May 30, 7:12AM CDT
IDEXX (IDXX) started off 2016 on a strong note, with its first-quarter results squarely beating the Zacks Consensus Estimate.
BSX: 23.77 (-0.13), SRDX: 24.79 (+0.13), BAX: 46.49 (-0.16), IDXX: 94.60 (-0.36)
Cepheid: GeneXpert Placements High, Currency Woes Stay
Zacks Equity Research - Zacks Investment Research - Fri May 27, 6:51AM CDT
Cepheid (CPHD) started 2016 on a promising note with its first-quarter results squarely beating the Zacks Consensus Estimate.
BSX: 23.77 (-0.13), SRDX: 24.79 (+0.13), BAX: 46.49 (-0.16), CPHD: 33.40 (unch)
Qiagen, Therawis Diagnostics to Develop Breast Cancer Test
Zacks Equity Research - Zacks Investment Research - Fri May 27, 6:47AM CDT
With the global cancer diagnostic market expected to grow at a CAGR of 7.6% to $168.6 billion by 2020, we expect Qiagen (QGEN) to garner higher profits on account of this collaboration.
BSX: 23.77 (-0.13), SRDX: 24.79 (+0.13), BAX: 46.49 (-0.16), QGEN: 22.04 (-0.11)
ResMed Posts Mixed Q3 Results, Brightree Buyout on Track
Zacks Equity Research - Zacks Investment Research - Thu May 26, 7:35AM CDT
ResMed (RMD) posted a lackluster third-quarter fiscal 2016. Nevertheless, ResMed's segmental as well as geographical performance was strong.
BSX: 23.77 (-0.13), SRDX: 24.79 (+0.13), BAX: 46.49 (-0.16), RMD: 64.28 (-0.23)
ResMed: Positive CAT-HF Study Results to Drive ASV Sales
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:51AM CDT
The positive CAT-HF study results encourage us to expect a rise in demand for the wide range of products offered by ResMed (RMD) in the respiratory care market.
BSX: 23.77 (-0.13), SRDX: 24.79 (+0.13), BAX: 46.49 (-0.16), RMD: 64.28 (-0.23)
Edwards Lifesciences: Q1 Strong, TAVR Prospects Bright
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:50AM CDT
Edwards Lifesciences (EW) made a strong start to 2016, with its first-quarter results beating estimates on both the fronts.
BSX: 23.77 (-0.13), SRDX: 24.79 (+0.13), BAX: 46.49 (-0.16), EW: 104.48 (-0.24)
Baxter Unveils THERANOVA Dialyser at ERA-EDTA Congress
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:42AM CDT
Baxter International Inc. (BAX) recently showcased THERANOVA, a new class of medium cut-off (MCO) dialysers.
SRDX: 24.79 (+0.13), IRMD: 21.75 (-0.38), MASI: 52.45 (+0.12), BAX: 46.49 (-0.16)
Baxter (BAX) Raised to Strong Buy on Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:22AM CDT
On May 20, Zacks Investment Research raised Baxter International Inc. (BAX) to a Zacks Rank #1 (Strong Buy).
SRDX: 24.79 (+0.13), MASI: 52.45 (+0.12), BAX: 46.49 (-0.16), EW: 104.48 (-0.24)
Quality Systems (QSII) Q4 Earnings Disappoint, Stock Falls
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:21AM CDT
Shares of Quality Systems Inc. (QSII) plunged almost 10% in after-hours trading following the company's disappointing fourth-quarter fiscal 2016 results.
SRDX: 24.79 (+0.13), MASI: 52.45 (+0.12), EW: 104.48 (-0.24), QSII: 12.60 (+0.16)
Boston Scientific's Full-Body MRI SCS System Gets FDA Nod
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:20AM CDT
Boston Scientific's (BSX) Precision Montage MRI SCS allows patients to undergo a full-body 1.5 Tesla MRI scan while also delivering multiple waveforms.
BSX: 23.77 (-0.13), SRDX: 24.79 (+0.13), BAX: 46.49 (-0.16), LMAT: 13.64 (-0.06)
Masimo (MASI) Scales a 52-Week High on Strong Q1 Results
Zacks Equity Research - Zacks Investment Research - Thu May 19, 7:16AM CDT
Shares of Masimo Corp (MASI) scaled a new 52-week high of $48.87 on May 18, eventually closing a tad bit lower at $48.51.
SRDX: 24.79 (+0.13), IRMD: 21.75 (-0.38), MASI: 52.45 (+0.12), EW: 104.48 (-0.24)
STERIS (STE) Misses on Q4 Earnings, Higher Tax a Concern
Zacks Equity Research - Zacks Investment Research - Thu May 19, 5:32AM CDT
STERIS (STE) ended fiscal 2016 on a disappointing note, with its fourth-quarter results missing the Zacks Consensus Estimate on both the fronts
BSX: 23.77 (-0.13), SRDX: 24.79 (+0.13), STE: 69.09 (-0.07), BAX: 46.49 (-0.16)
Strong Q4 for PetMed (PETS), New Order & Reorder Sales Gain
Zacks Equity Research - Zacks Investment Research - Thu May 19, 5:19AM CDT
On May 13, 2016, we issued an updated research report on PetMed Express (PETS).
SRDX: 24.79 (+0.13), MASI: 52.45 (+0.12), PETS: 19.29 (+0.05), EW: 104.48 (-0.24)
SurModics Up 17.0% Since SmarTrend Uptrend Call (SRDX)
Comtex SmarTrend(R) - Fri Jul 08, 1:30AM CDT
SmarTrend identified an Uptrend for SurModics (NASDAQ:SRDX) on January 28th, 2016 at $20.44. In approximately 5 months, SurModics has returned 16.96% as of today's recent price of $23.90.
SRDX: 24.79 (+0.13)
Zacks.com featured highlights: Copart, Tallgrass Energy GP, Vishay Intertechnology, W.R. Grace and SurModics
Zacks Equity Research - Zacks Investment Research - Thu Jun 30, 8:30AM CDT
Zacks.com featured highlights: Copart, Tallgrass Energy GP, Vishay Intertechnology, W.R. Grace and SurModics
SRDX: 24.79 (+0.13), GRA: 73.95 (-0.27), VSH: 12.13 (+0.05), CPRT: 50.01 (+0.16), TEGP: 24.24 (+0.37)
Invest in These 5 Efficient Stocks for Healthy Returns
Zacks Equity Research - Zacks Investment Research - Wed Jun 29, 7:03AM CDT
An investment strategy based on the efficiency level of a company is likely to lead to healthy returns across all market conditions.
SRDX: 24.79 (+0.13), GRA: 73.95 (-0.27), VSH: 12.13 (+0.05), CPRT: 50.01 (+0.16), TEGP: 24.24 (+0.37)
Myriad Genetics Buys Sividon Diagnostics, Gains EndoPredict
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 7:59AM CDT
With the global cancer diagnostic market currently expected to grow at a CAGR of 7.6% to $168.6 billion by 2020; we expect the Sividon acquisition to open up more opportunities for Myriad (MYGN) in this market.
BSX: 23.77 (-0.13), SRDX: 24.79 (+0.13), MYGN: 32.06 (+0.37), BAX: 46.49 (-0.16)
SurModics to Present at Jefferies Healthcare Conference
BusinessWire - Wed Jun 01, 7:05AM CDT
SurModics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced that Gary Maharaj, president and chief executive officer, and Andy LaFrence, vice president of finance and chief financial officer, will make a presentation to the investment community at the Jefferies Healthcare Conference in New York City on Tuesday, June 7, 2016, at 4 p.m. ET (3 p.m. CT).
SRDX: 24.79 (+0.13)
GNC Holdings Q1 Results Weak, Overseas Prospects Bright
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 7:01AM CDT
GNC Holdings (GNC) made a disappointing start to its first quarter of 2016 with the results squarely missing the Zacks Consensus Estimate.
BSX: 23.77 (-0.13), SRDX: 24.79 (+0.13), BAX: 46.49 (-0.16), GNC: 25.75 (+0.22)
Thermo Fisher to Buy FEI, Boost Electron Microscopy Platform
Zacks Equity Research - Zacks Investment Research - Tue May 31, 7:58AM CDT
The FEI deal is expected to be accretive to Thermo Fisher's (TMO) adjusted EPS by 30 cents in the first full year after close.
BSX: 23.77 (-0.13), SRDX: 24.79 (+0.13), TMO: 152.34 (-0.35), BAX: 46.49 (-0.16), FEIC: 106.79 (+0.01)
IDEXX Laboratories: Strong Instrument Placement Drives Q1
Zacks Equity Research - Zacks Investment Research - Mon May 30, 7:12AM CDT
IDEXX (IDXX) started off 2016 on a strong note, with its first-quarter results squarely beating the Zacks Consensus Estimate.
BSX: 23.77 (-0.13), SRDX: 24.79 (+0.13), BAX: 46.49 (-0.16), IDXX: 94.60 (-0.36)
Cepheid: GeneXpert Placements High, Currency Woes Stay
Zacks Equity Research - Zacks Investment Research - Fri May 27, 6:51AM CDT
Cepheid (CPHD) started 2016 on a promising note with its first-quarter results squarely beating the Zacks Consensus Estimate.
BSX: 23.77 (-0.13), SRDX: 24.79 (+0.13), BAX: 46.49 (-0.16), CPHD: 33.40 (unch)
Qiagen, Therawis Diagnostics to Develop Breast Cancer Test
Zacks Equity Research - Zacks Investment Research - Fri May 27, 6:47AM CDT
With the global cancer diagnostic market expected to grow at a CAGR of 7.6% to $168.6 billion by 2020, we expect Qiagen (QGEN) to garner higher profits on account of this collaboration.
BSX: 23.77 (-0.13), SRDX: 24.79 (+0.13), BAX: 46.49 (-0.16), QGEN: 22.04 (-0.11)
ResMed Posts Mixed Q3 Results, Brightree Buyout on Track
Zacks Equity Research - Zacks Investment Research - Thu May 26, 7:35AM CDT
ResMed (RMD) posted a lackluster third-quarter fiscal 2016. Nevertheless, ResMed's segmental as well as geographical performance was strong.
BSX: 23.77 (-0.13), SRDX: 24.79 (+0.13), BAX: 46.49 (-0.16), RMD: 64.28 (-0.23)
ResMed: Positive CAT-HF Study Results to Drive ASV Sales
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:51AM CDT
The positive CAT-HF study results encourage us to expect a rise in demand for the wide range of products offered by ResMed (RMD) in the respiratory care market.
BSX: 23.77 (-0.13), SRDX: 24.79 (+0.13), BAX: 46.49 (-0.16), RMD: 64.28 (-0.23)
Edwards Lifesciences: Q1 Strong, TAVR Prospects Bright
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:50AM CDT
Edwards Lifesciences (EW) made a strong start to 2016, with its first-quarter results beating estimates on both the fronts.
BSX: 23.77 (-0.13), SRDX: 24.79 (+0.13), BAX: 46.49 (-0.16), EW: 104.48 (-0.24)
Baxter Unveils THERANOVA Dialyser at ERA-EDTA Congress
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:42AM CDT
Baxter International Inc. (BAX) recently showcased THERANOVA, a new class of medium cut-off (MCO) dialysers.
SRDX: 24.79 (+0.13), IRMD: 21.75 (-0.38), MASI: 52.45 (+0.12), BAX: 46.49 (-0.16)
Baxter (BAX) Raised to Strong Buy on Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:22AM CDT
On May 20, Zacks Investment Research raised Baxter International Inc. (BAX) to a Zacks Rank #1 (Strong Buy).
SRDX: 24.79 (+0.13), MASI: 52.45 (+0.12), BAX: 46.49 (-0.16), EW: 104.48 (-0.24)
Quality Systems (QSII) Q4 Earnings Disappoint, Stock Falls
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:21AM CDT
Shares of Quality Systems Inc. (QSII) plunged almost 10% in after-hours trading following the company's disappointing fourth-quarter fiscal 2016 results.
SRDX: 24.79 (+0.13), MASI: 52.45 (+0.12), EW: 104.48 (-0.24), QSII: 12.60 (+0.16)
Boston Scientific's Full-Body MRI SCS System Gets FDA Nod
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:20AM CDT
Boston Scientific's (BSX) Precision Montage MRI SCS allows patients to undergo a full-body 1.5 Tesla MRI scan while also delivering multiple waveforms.
BSX: 23.77 (-0.13), SRDX: 24.79 (+0.13), BAX: 46.49 (-0.16), LMAT: 13.64 (-0.06)
Masimo (MASI) Scales a 52-Week High on Strong Q1 Results
Zacks Equity Research - Zacks Investment Research - Thu May 19, 7:16AM CDT
Shares of Masimo Corp (MASI) scaled a new 52-week high of $48.87 on May 18, eventually closing a tad bit lower at $48.51.
SRDX: 24.79 (+0.13), IRMD: 21.75 (-0.38), MASI: 52.45 (+0.12), EW: 104.48 (-0.24)
STERIS (STE) Misses on Q4 Earnings, Higher Tax a Concern
Zacks Equity Research - Zacks Investment Research - Thu May 19, 5:32AM CDT
STERIS (STE) ended fiscal 2016 on a disappointing note, with its fourth-quarter results missing the Zacks Consensus Estimate on both the fronts
BSX: 23.77 (-0.13), SRDX: 24.79 (+0.13), STE: 69.09 (-0.07), BAX: 46.49 (-0.16)
Strong Q4 for PetMed (PETS), New Order & Reorder Sales Gain
Zacks Equity Research - Zacks Investment Research - Thu May 19, 5:19AM CDT
On May 13, 2016, we issued an updated research report on PetMed Express (PETS).
SRDX: 24.79 (+0.13), MASI: 52.45 (+0.12), PETS: 19.29 (+0.05), EW: 104.48 (-0.24)
